NOTE: This test is ONLY AVAILABLE TO AUSTRALIAN RESIDENTS.
S-Adenosylmethionine (SAMe), derived from methionine, is a universal methyl donor involved in methylation reactions. These reactions are crucial for DNA synthesis, mental health, and detoxification. SAMe also supports joint health, cancer management, and mood regulation, making it a valuable compound for managing conditions like depression, osteoarthritis, and liver disease. SAMe levels reflect the body’s ability to methylate (via methylation), and testing SAMe can help identify potential methylation deficiencies or imbalances.
S-Adenosylhomocysteine (SAH) is a precursor to homocysteine and a byproduct of SAMe-dependent methylation reactions. Elevated SAH levels can indicate impaired methylation efficiency, potentially contributing to various health issues, including cardiovascular disease and neurological conditions.
Monitoring SAMe and SAH levels can provide insights into methylation status and guide interventions to support optimal health.
What we test?
- S-adenosyl-L-methionine SAH
- S-adenosylhomocysteine
- SAMe
Common conditions
- Cardiovascular Disease
- Fertility
- Endocrine and hormone imbalances
- Methylation imbalances
- Mood disorders
- Neurological disorders
About The SAM & SAH Test
After you purchase the test, you will receive a simple blood test kit in the mail. The test kit comes with:
- An authorized blood specimen order form that you take to your local accredited pathology for collection of your blood (Find a pathology near you here).
- A blood specimen test kit for the pathology to use to collect your blood sample
- Complete instructions for taking the test for you and the pathology
Test results are sent to one of our professional health practitioners within 10-14 business days for evaluation. Our practitioners contact you with the results and recommendations on any findings via email, mail or phone.*
Have any questions about this test? Ask one of our qualified health practitioners here.
*This test is subject to our terms and conditions.
